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Background: The genetic heterogeneity of sensorineural hearing loss is a major hurdle to the efficient discovery of
disease-causing genes. We designed a multiphasic analysis of copy number variation (CNV), linkage, and single
nucleotide variation (SNV) of whole exome sequencing (WES) data for the efficient discovery of mutations causing
nonsyndromic hearing loss (NSHL).
Results: From WES data, we identified five distinct CNV loci from a NSHL family, but they were not co-segregated
among patients. Linkage analysis based on SNVs identified six candidate loci (logarithm of odds [LOD] >1.5). We
selected 15 SNVs that co-segregated with NSHL in the family, which were located in six linkage candidate loci.
Finally, the novel variant p.M305T in ACTG1 (DFNA20/26) was selected as a disease-causing variant.
Conclusions: Here, we present a multiphasic CNV, linkage, and SNV analysis of WES data for the identification of a
candidate mutation causing NSHL. Our stepwise, multiphasic approach enabled us to expedite the discovery of
disease-causing variants from a large number of patient variants.
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By virtue of the recent development of massively parallel
DNA sequencing technologies, access to genomic com-
position has become easier than ever. With the advantage
of exome sequencing, many studies have identified causal
variants responsible for numerous disorders. Exome se-
quencing provides a particularly powerful method with
which to identify disease-causing single nucleotide varia-
tions (SNVs) in Mendelian disorders [1-4]. Though whole
exome sequencing (WES) has been used to successfully
discover many genes that cause Mendelian disorders, ana-
lysis of WES data remains challenging [1]. An individual
exome has more than 20,000 variants compared with the
reference genome. Even in familial Mendelian disorders,* Correspondence: woongyang.park@samsung.com; choiby@snubh.org
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reproduction in any medium, provided the orthe overall success rate for identifying disease-causing
genes is around 50% [5]. Thus, many of the potential rea-
sons for failure in the WES approach need to be solved
fully in order to realize the promise of WES for routine
diagnosis of Mendelian disorders.
Filtering patient data against normal populations and in-
ferring identity-by-descent (IBD) in family studies can en-
rich candidate genes [4,6]. Genetic linkage analysis has
also been a powerful tool for isolating potential causal can-
didate variants. A two-step approach of linkage analysis
using single nucleotide polymorphism (SNP) microarrays
to detect high logarithm of odds (LOD) score regions and
subsequent targeted re-sequencing of regions of interest
has been utilized in many genomic studies to intensify the
power of detection [7]. Classically, microsatellite markers
have been used for linkage analysis, and now millions of
dimorphic SNP markers can be used to provide higher
resolution in order to pinpoint candidate loci [8]. Cur-
rently, there are many efforts to use coding SNP informa-
tion from WES data to facilitate genetic linkage mapping.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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establish multiphasic exome analyses based on linkages
and SNVs [4,9].
Copy number variation (CNV) has been implicated in
both Mendelian diseases [10] and common diseases such
as obesity [11] and schizophrenia [12]. The presence of
large insertions or deletions in patients is typically investi-
gated prior to SNV analysis by karyotyping, fluorescence
in situ hybridization (FISH), and/or array comparative
genome hybridization (aCGH). Estimation of CNV is a
challenging aspect of WES analysis, in which local depths
of coverage must be mapped to copy numbers. Indeed,
aCGH has limitations in detecting high CNV regions.
Conversely, CNV data based on WES provides more ac-
curate copy numbers because the depths of exon coverage
from WES data vary linearly with real copy numbers [13].
Bioinformatics tools to analyze copy numbers from WES
data are now publicly available [14].
Nonsyndromic hearing loss (NSHL) contributes to more
than 70% of inherited cases of hearing loss. To date, ap-
proximately 50 genes have been shown to be causally
related to NSHL. Many studies have identified more than
129 loci responsible for NSHL; however, 47 loci have not
yet been mapped to proper genes [15,16]. The complexity
of the auditory system may explain why so many genes
and loci are linked to hearing loss. The genetic causes of
hearing loss can be detected by sequence analysis, which
helps clinicians and patients to delineate the basis of the
disease. Given that hearing loss in early childhood can
affect linguistic development [16], it is important to im-
prove current techniques for identifying genetic alter-
ations that cause NSHL. Earlier identification of such
alterations in patients and families may allow for better
clinical management of NSHL.
Analysis of WES data can be expanded to obtain more
information useful for identifying causative mutations in
Mendelian diseases. In this paper, in order to analyze
WES data from an entire family, we applied three differ-
ent methods, namely, CNV, linkage, and segregation
analysis. By combining the results obtained from these
methods, we efficiently identified a causative mutation
from the family data. We applied this approach to WES
data from a NSHL family to identify candidate disease-
causing variants.
Results
Clinical features of a NSHL family
We identified a Korean family with six members affected
by NSHL and seven unaffected members (Figure 1A).
Pure tone audiometry (PTA) was performed on nine fam-
ily members, three of whom (II-2, II-3, and II-5) exhibited
profound post-lingual hearing loss. The three members
had normal cognitive function and no anomalous-looking
features. They went through a battery of clinical testsranging from general physical examinations, chest X-rays,
and simple blood tests to detailed imaging studies includ-
ing brain MRI and temporal bone CT scans. No abnorma-
lities were detected in the tests, excluding the possibility
that hearing loss in these patients was syndromic. The
other siblings (II-1, II-7, and II-9) exhibited normal hearing
(Figure 1B). Patients II-2, II-3, and II-5 estimated that their
hearing loss became severe in their 30’s, during which time
they started to wear hearing aids. Their hearing loss was
further aggravated and became profound in their late for-
ties. Ultimately, patients II-3 and II-5 no longer benefited
from hearing aids and underwent cochlear implantation.
They achieved recognition of common sentences without
lip reading one year after implantation. GJB2 is one of the
most frequently detected genes in individuals with NSHL,
and thus we first investigated the sequence of GJB2 in the
NSHL patients. After failing to identify any mutations
in GJB2, we performed WES on several members of
the Korean family in order to identify a disease-causing
mutation.
Copy number analysis using WES data
WES data was obtained from the parents and six siblings
(four affected and four unaffected members, Figure 1A).
The mean coverage of each sample ranged from 40.3X to
51.3X, and 87.0% to 90.5% of the targeted exome had at
least 10 reads. A multiphasic WES analysis was designed
to find a causative NSHL mutation (Figure 1C). First, we
investigated co-segregation of copy number duplication or
deletion in exomes of patients using CONTRA software.
We detected five CNV loci with distinct features in the
plots (Figure 2A). None of the CNVs co-segregated with
affected or unaffected family members. One CNV locus of
the CNVs from three members (high copy number exons
in II-9, and low copy number exons in II-3 and II-7) was
located in 8p23.1, a region that contains beta-defensin
genes and SPAG11 (Figure 2B). The following genes were
identified as being located at regions of distinct CNVs in
the indicated family members: GSTM1 in 1p13.3 (I-1, II-3,
II-7, and II-9) (Figure 2C), UGT2B17 in 4q13.2 (I-2 and
II-7), BNTL3 in 5q35.3 (II-1), and LILRB2 in 19q13.4 (I-2)
(data not shown). We also applied Fisher’s exact test for
the LOD score per exon to detect co-segregated regions
of CNVs, but there were no peaks with values reaching
significance. We identified two groups based on the pat-
tern of segregation of SPAG11, GSTM1, and beta-defensin
genes to validate the relevance of this method (Figure 2D).
Exome linkage analysis
Because the pedigree strongly suggested an autosomal
dominant mode of inheritance, we identified 17,498 cod-
ing autosomal SNVs from WES data and performed
single-point linkage analysis. We identified six hot spots
where a number of peaks were closely clustered (Figure 3).
Figure 1 NSHL family pedigree and clinical features. Pedigree with phenotype and experimental information. Black and white denote
affected and unaffected subjects, respectively, while shaded grey represents equivocal hearing status (A). Typical audiograms of affected and
unaffected subjects (B). Scheme of the multiphasic analysis of WES data (C).
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13, 14, 16, and 17 consisting of 11, 67, 2, 13, 17, and 13
exons, respectively.
We validated single-point linkages using a SNP micro-
array containing 328,125 SNPs. Along with the eight initial
family members recruited for WES analysis, we included
three additional subjects (II-4, III-1, and III-4) to validate
the significance of peaks obtained from exome linkage
analysis. The six hot spots detected from sequencing data
were also detected in microarray analysis with a relatively
high LOD score (Figure 3). Adding three more subjects to
the linkage analysis enhanced the peaks at chromosomes
11 and 17, which consisted of one and three SNPs (LOD
score >2), respectively. The genotype patterns of these
four peaks were perfectly matched with an autosomal
dominant mode of inheritance.
SNV analysis
Based on the WES analysis of four affected and four
unaffected family members, we identified 18,748~20,025
SNVs and 413~457 indels. These were reduced to
962~1,123 SNVs and 140~153 indels after filteringthrough the dbSNP135 and 1000 Genome databases. Fif-
teen variants causing amino acid changes were selected
based on their co-segregation pattern within the family
(Table 1). All of the 15 variants on chromosomes 3, 11, 13,
16, and 17 corresponded to regions with high LOD scores
(Figure 3). One novel mutation in actin gamma 1 (ACTG1)
was identified, consisting of a methionine to threonine sub-
stitution at amino acid 305 (p.M305T), This candidate vari-
ant was validated by Sanger sequencing and co-segregated
with hearing loss in all family members (Figure 4A and B).
ACTG1 (DFNA20/26; MIM: 604717) was strictly con-
served in 19 of 20 eukaryotes analyzed (HomoloGene:74402),
with the M305 codon being conserved in 19 species. Protein
damage prediction analysis identified p.M305T as “possibly
damaging” by HumDiv, “probably damaging” by HumVar in
Polyphen2 [17], and “disease causing” by MutationTaster
[18]. The mutation site, Met305, was visualized using the
3D structure of bovine beta-actin bound by adenosine
triphosphate (ATP) with profilin (Figure 4C). The methio-
nine was closely located to the ATP molecule. Addition-
ally, Met305 is listed as a predicted residue for the ATP
binding site by the Protein Data Bank (PDB).
Figure 2 CNV detected by WES. CNV throughout the chromosomes – 1p13.3, 4q13.2, 5q35.3, 8p23.1, and 19q13.4 have distinct CNVs (14q32.3
is distinct, but contains variable regions associated with antibody production) (A), 8p23.1 containing beta-defensin clusters (B), and 1p13.1
containing GSTM1 (C) of eight subjects. Red and green dots are exons with p<0.05. Co-segregated regions of CNVs were also analyzed by Fisher’s
exact test (D).
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WES is a powerful technique that can be used to discover
causative genes in human diseases. Although WES has
been integral in identifying more than 1,000 novel genes
in Mendelian disorders [1], there is still a need for in-
creased efficiency of gene discovery using WES data. In
this regard, we analyzed WES data from a family with a
history of NSHL by focusing on three categories of genetic
information: CNVs, linkage analysis, and SNVs. Utilizing
these data, we undertook a stepwise multiphasic approach
to identify disease-causing variations in the family.
8p23.1, which contains a beta-defensin cluster, was
detected as a region with high copy number (II-9) and low
copy number (II-3 and II-7) (Figure 2). The defensin clus-
ter, containing both alpha- and beta-defensins, was previ-
ously studied as a dynamic genomic region with varying
copy numbers ranging from one to twelve [19]. The par-
ents had normal copy numbers, which was in contrast to
the low copy numbers seen in two children and high copy
number observed in one child. A total of four haplotypes
of 8p23.1 may have been inherited in this family, and each
parent may have had both under- and over-amplified al-
leles of 8p23.1. The overall copy number of a parent canappear to be normal due to compensation of copy number
from over- to under-amplified alleles [20]. In the family in
this study, GSTM1 and UGT2B17, genes with frequently
reported deletions [21], as well as BNTL3 and LILRB2,
exhibited CNVs. We used Fisher’s exact test on the af-
fected and unaffected family members after validating this
method for 8p23.1 and GSTM1 groups to determine the
amplification or deletion of multiple exons that matched
the co-segregation pattern of the disease. Multiple statisti-
cally significant peaks at 8p23.1 and GSTM1 were identi-
fied, and were identical to plots from the first approach.
However, there was only one statistically significant peak
identified by testing the two groups that segregated with
the disease, and this peak did not correlate with disease
status. Thus, while WES may provide a method to identify
CNV regions with highly similar sequences, determining
accurate copy numbers can prove difficult.
Linkage analysis was performed to narrow down the
number of candidates based on WES data. Importantly,
linkage analysis with a relatively small number of markers
still provides useful information. Fewer markers from WES
data are available and can be obtained from a SNP micro-
array, and the markers that are identified may not be evenly
Figure 3 A multiphasic analysis of WES data. WES data were analyzed for exon CNVs and SNVs. Fisher exact test on CNVs detected one exon
segregating with NSHL on chr19 (top). Linkage analysis with SNVs called by Exome-seq identified six disease-linked “hot spots” on chr3, chr11,
chr13, chr14, chr16, and chr17 (middle). Segregation analysis independently identified 15 SNVs co-segregating with NSHL (green dots). Among
them, a novel variant resulting in p.M305T, in ACTG1 on chr17 was validated with Sanger sequencing (red dot). Linkage analysis was also
performed with SNP microarray by adding three more subjects in the family. Not only were similar “hot spots” detected, adding more subjects in
the analysis enhanced the true peak (red arrow) (bottom).
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sider the potential disadvantages of this approach. Because
we analyzed only exonic SNPs (~1% of genome-wide
SNPs), we may have lost critical information located out-
side of exons. In addition, potential genotyping errors in
linkage analyses can reduce statistical power for detecting
linkage peaks or result in false positive linkage peaks [22].
Even so, the results obtained from the different data sets in
this study confirmed the validity of our approach. LinkageTable 1 Nonsynonymous SNVs and indels identified in patien
Gene Chr Nucleotide variation Amino aci
MED12L chr3 c.G3629A p.R1
VEPH1 chr3 c.T1564C p.S5
CWF19L2 chr11 c.A2681G p.Y8
CEP164 chr11 c.G281A p.S
OR6T1 chr11 c.G465C p.W1
OR8G5 chr11 c.G287A p.C
OR8G5 chr11 c.G716A p.G2
ROBO3 chr11 c.G1247A p.R4
SKA3 chr13 c.A1157G p.K3
SKA3 chr13 c.C1142T p.T3
SKA3 chr13 c.G559A p.V1
SKA3 chr13 c.208delC p.Q
NECAB2 chr16 c.C704G p.T2
DPEP1 chr16 c.G1051C p.E3
ACTG1 chr17 c.T914C p.Manalysis requires a large number of subjects to help identify
putative loci. Unless a proper number of subjects are avail-
able, an informative result is difficult to obtain.
After applying linkage analysis results, the co-segregated
variants were all found to be located in the loci of high
LOD scores. However, linkage analysis can decrease the
number of candidate variants, particularly in instances
where candidate variants are widely distributed. Additional
linkage analysis of WES data demonstrated a similarts but not in non-symptomatic family members
















Figure 4 p.M305T mutation in ACTG1. The p.M305T mutation reported in this study as well as several other previously reported mutations in
ACTG1 cause hearing loss (A). p.M305T (arrow), confirmed by Sanger sequencing, co-segregated perfectly with hearing loss (asterisk: synonymous
SNV) (B). Met305 is located close to the ATP binding site of ACTG1 (C).
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eously generated results during variant calling. Considering
that CNVs could be also detected using this approach, the
multiphasic analysis of WES data efficiently narrowed and
identified candidate variants and was advantageous com-
pared with established methods such as initial aCGH, vari-
ant calling according to WES data alone, or linkage
analysis based on SNP microarray data.
Actin is a highly conserved cytoskeletal protein that
plays important roles in eukaryotic cell processes such as
cell division, migration, endocytosis, and contractility.
Actin isoforms are classified into two groups based on
expression patterns. ACTA1, ACTA2, ACTC, and ACTG2
are “muscle” actins, predominantly expressed in striated
or smooth muscle, whereas ACTB and ACTG1 are
cytoplasmic “non-muscle” actins [23]. Autosomal domin-
ant progressive sensorineural hearing loss, DFNA20/26
(MIM: 604717), is caused by a mutation in the gamma-
actin gene on chromosome 17 at q25.3. Some ACTG1
mutations are associated with Baraitser-Winter syndrome,
which is characterized by developmental delay, facial
dysmorphologies, brain malformations, colobomas, and
variable hearing loss. The constellation of these abnormal-
ities is suggested as the most severe phenotype of ACTG1
mutations [24,25]. A genome-wide screen of DFNA20
localized candidates to 17q25.3 [26] and mapped the
causative missense mutations to highly conserved actin
domains of the gamma-actin gene (ACTG1) [27,28]. In
vivo and in vitro studies of ACTG1 indicate that it is re-
quired for reinforcement and long-term stability of actin
filamentous structures of stereocilia, but not for auditory
hair cell development, which is in line with the progressivenature of hearing loss related to ACTG1 mutations in
humans [29,30]. Further, missense mutations in either
ACTB or ACTG1 have recently been reported to cause
Baraitser-Winter syndrome. Interestingly, of the 11 muta-
tions that cause DFNA20 [27,28,31-34] and 6 mutations
that cause Baraitser-Winter syndrome (see OMIM entry -
*102560) that have been reported, are all missense muta-
tions. The predicted interaction between Met305 and ATP
in bovine beta-actin, a protein with a 99% identity to
ACTG1, implies that the mutation of Met305 may influ-
ence ATP binding of ACTG1, which is essential for
polymerization of G-actin to F-actin.
ACTG1 is predominantly expressed in intestinal epi-
thelial and auditory hair cells [35]. Detection of exclu-
sively missense mutations in this gene may imply that
truncating mutations have more severe effects and might
cause embryonic lethality. The hearing impaired subjects
in this study (II-2, II-3, and II-5) did not report any
gastrointestinal complaints. The subjects in this study
required cochlear implants, recapitulating what has pre-
viously been reported regarding the management of pa-
tients with mutations in ACTG1 and resultant NSHL
[31]. The severe phenotype and rapid progression of
hearing loss to a profound level within one or two de-
cades associated with mutations in ACTG1 necessitates
an early molecular genetic diagnosis and timely auditory
rehabilitation.
Conclusions
Two or more platforms (aCGH, SNP array, and WES)
have previously been required to generate complex gen-
etic information such as CNVs, linkages, SNVs, and
Table 2 Exon copy number variation contingency based
on the whole per-exon CNV status
Copy number Patient Normal Total
gain n21 n20 n2+
normal n11 n10 n1+
loss n01 n00 n0+
n+1 n+0 8
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has primarily been utilized to obtain only SNVs and
indels. Our study agrees well with other work demon-
strating that analysis of WES data also allows for CNV
and linkage determination due to its quantitative traits.
Given the robust nature of WES data, it is clear that the
full capabilities of this relatively new technology have
not yet been fully realized. Our multiphasic WES ana-
lysis proved very powerful for the interpretation and
narrowing of WES results, in particular when a large
amount of family data is available.
Methods
Subjects
This study was approved by the Institutional Review
Boards (IRBs) of Seoul National University Hospital
(SNUH) and Seoul National University Bundang Hos-
pital (SNUBH). Written informed consent for participa-
tion in the study was obtained from participants or from
a parent or guardian in the case of child participants. A
three generation pedigree was established for the family
(SNUH3) (Figure 1A). Among the 15 subjects in the
SNUH3 family, 13 were willing to participate in this gen-
etic study, while two reportedly deaf subjects (II-8 and
III-3) refused participation. DNA from blood lympho-
cytes was isolated from the 12 subjects, while DNA from
III-2 was obtained with a buccal swab.
Audiometric analysis
Pure tone and speech audiometry and physical examina-
tions were performed for nine members of the cohort
(Figure 1B). Pure tone audiometry (PTA) with air and
bone conduction at frequencies ranging from 250 to
8,000 Hz was obtained from the recruited subjects
according to standard protocols. The auditory phenotype
was inferred from thorough medical and developmental
history interviews from one deaf subject (I-1), two likely
unaffected subjects (I-2 and III-2), and one subject (II-6)
with an equivocal hearing status.
WES
Eight of the 13 recruited subjects (four affected and four
unaffected) were chosen for commercial WES (Otogenetics,
Norcross, GA) and analyzed as previously reported [3].
Briefly, paired-end reads of 100 bp from the eight subjects
were aligned by bwa-0.6.1 to the UCSC hg19 reference
genome using default settings. SAMtools and Picards were
used to process SAM/BAM files and mark duplicates. Local
realignment around indels and base quality score reca-
libration was done for each sample, and variants were
called by a unified genotyper in GATK-1.3. Perl scripts and
ANNOVAR were used to annotate variants and search the
relevant known SNPs and indels from dbSNP135 and the
1000 Genome database. Variants with a read depth greaterthan 10 and genotype quality score greater than 30 were fil-
tered for further analysis.
CNV analysis using WES data
CNVs were detected by CONTRA software [36] using
BEDTools to calculate coverage per exon and apply sta-
tistics to normalize coverage data and test fold changes.
A new baseline file was produced using our data, but we
expected to detect distinct deletions or amplifications.
Polymerase chain reaction (PCR) duplicates were re-
moved by Picards before using CONTRA.
We tabulated a 3 × 2 exon copy variation contingency
table based on the whole per-exon CNV status of the
eight subjects (Table 2). Fisher’s exact test was used to
assess the significance of differences between propor-
tions of abnormal copy number events present in af-
fected and unaffected family members. We assumed that
all of the subjects were independent in order to conduct
an alternative practical method to find loci that segre-
gated with the disease.
Linkage analysis using WES and SNP microarray data
Using WES data, we filtered out the following variants:
those located on sex chromosomes, those with low
coverage (<10X), and those with a low genotype quality
score (<30) in any of the eight subjects with 17,498
SNVs. We used a Genome-Wide Human SNP Array 6.0
(Affymetrix, Santa Clara, CA), which contains 328,125
SNP markers located on autosomal chromosomes. We
performed parametric linkage analysis with the R package
paramlink [37]. The pedigree suggested an autosomal
dominant mode of inheritance, and thus we assumed an
autosomal dominant model with default values of full
penetrance (f0, f1, f2) = (0, 1, 1) and disease allele fre-
quency = 1e-05. The penetrance parameters f0, f1, and f2
were also defined using conventional notation as below.
f i ¼ P affected i copies of the disease allelej Þð
The recombination fraction between the disease locus
and markers was set to θ=0 by default. We computed
single-point LOD scores for all markers. We compared
LOD scores from SNP microarray and WES. We matched
the subjects and the markers that were common between
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single-point analyses were performed with all of the data.
3D structure of actin gamma-1 (ACTG1)
Protein damage prediction analysis was performed using
HumDiv and HumVar in Polyphen2 [17], and also by
MutationTaster [18]. The mutation site was visualized using
the 3D structure of bovine beta-actin bound by adenosine
triphosphate (ATP) with profilin. Bovine beta-actin actin
has a 99% identity with human gamma-actin. The ATP
binding site was analyzed using the Research Collaboratory
for Structural Bioinformatics (RCSB) Protein Data Bank
(PDB) (www.pdb.org) [38]. PDB entry 2BTF [39] on
P60712 (ACTB_BOVIN) with P02584 (PROF1_BOVIN)
was downloaded, visualized, and modified by Bioclipse [40]
to observe the 305Met residue in 3D.
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